Robert S. Friedman M.D., F.A.C.S.

	Robert S. Friedman M.D., F.A.C.S.

Specialties:
Cataract Surgery
Glaucoma Surgery

Locations:
Sarasota, FL

EDUCATION

• Glaucoma Fellowship: New York Eye and Ear Infirmary, 1992-93
  Preceptor: Robert H. Ritch, M.D.
• Residency: Louisiana State University Eye Center, 1988-92
  Chairman: Herbert E. Kaufman, M.D.
• Internship: Michael Reese Hospital and Medical Center, 1987-88
• UHS/The Chicago Medical School, MD., 1987
• Vanderbilt University, B.A., 1983

EMPLOYMENT/ HOSPITAL AFFILIATIONS

Kantor Eye Institute & Laser Center, April 2000 to Present
Florida Eye Health, November 1999 to March 2000
Fort Lauderdale Eye Institute, September 1993 to October 1999

Sarasota Memorial Hospital
Doctor's Hospital of Sarasota
Center For Advanced Eye Surgery

CERTIFICATIONS

• Fellow, American College of Surgeons, 2003
• Diplomate, American Board of Ophthalmology, 1994
• Fellow, American Academy of Ophthalmology, 1994
• State of Florida Medical License #ME-0064752, 1993
• Diplomate, National Board of Medical Examiners, 1988
• VISX Excimer Laser System Certificate of Achievement: PRK, Myopic LASIK and Hyperopic LASIK

ASSOCIATIONS

• Florida Medical Association
• Sarasota County Medical Society

APPOINTMENTS AND HONORS

• Chief of Ophthalmology, Sarasota Memorial Hospital (2004-2005)
• Clinical Assistant Professor, Department of Ophthalmology, University of South Florida College of Medicine (2000 - Present)
• American Medical Association - Physician's Recognition Award (1999-2001)
• Alpha Omega Alpha Honor Medical Society
• The Chicago Medical School Dean's Award for Service to the School
• Cum Laude, Vanderbilt University
• Vanderbilt University Honor Council

CLINICAL INVESTIGATIONS

• March, 1994: Merck Protocol 047-00: A Parallel, Randomized, Double-Masked Study Comparing the 0.5% Timolol/2.0% MK-507 Combination Ophthalmic Solution to 0.5% Timolol Ophthalmic Solution or 2.0% MK-507 Ophthalmic Solution in Patients with Elevated Intraocular Pressure
• May, 1994: Insite Protocol C-93: A Three Month Study to Compare the Efficacy and Safety of 0.1% Betasite to 0.5% Betasite to 0.5% Betagan
• June, 1994: Merck Protocol 048-01: A One-Year, Parallel, Randomized, Double-Masked, Active-Controlled, Multiclinic Study Comparing the Corneal Safety of 2.0% MK-507 Ophthalmic Solution, 0.5% Timolol Ophthalmic Solution, and 0.5% Betaxolol Ophthalmic Solution in Patients with Elevated Intraocular Pressure with Ocular Hypertension or Glaucoma
• July, 1995: Alcon Laboratories Protocol C-95-48: A Three-Month, Multicenter, Triple-Masked, Primary Therapy Study of the Efficacy and Safety of BID and TID Dosed AL-4862 1.0% Ophthalmic Suspension Compared to TID Dosed Dorzolamide 2.0% and BID Dosed Timolol 0.5% in the Treatment of Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
• Caronia RM, Liebmann JM, Friedman R, Cohen H, Ritch R.: Trabeculectomy at the inferior limbus. Arch Ophthalmol 114:4:387-391, 1996.
• January, 1997: Allergan Protocol 192371-003-00: A Multicenter, Double-Masked, Randomized, Vehicle-Controlled, Parallel Group Study of the Safety and Efficacy of Cyclosporine 0.05% and 0.1% Ophthalmic Emulsions Used Twice Daily for Up to One Year in Patients with Moderate to Severe Keratoconjunctivitis Sicca
• October, 1997: Merck Protocol TRU414: A Parallel, Randomized, Double-Masked, Active Controlled, Multiclinic Study Comparing the Tolerability and Efficacy of 2.0% MK-507 Ophthalmic Solution and Orally Administered Acetazolamide in Patients with Ocular Hypertension or Glaucoma
• January, 1998: Alcon Laboratories Protocol C-97-72: A Six-Month, Triple-Masked, Parallel Group Therapy Study of the Safety and Efficacy of AL-6221 0.0015% and AL-6221 0.004% Compared to Timoptic 0.5% in Patients with Open-Angle Glaucoma or Ocular Hypertension
• March, 2001 Alcon Laboratories Protocol CM - 01 - 01: A Twelve Week Primary Therapy Study of the Safety and Efficiency of Travatan 0.004% in Patients Whose Intraocular Pressure is not Adequately Controlled on Timolol in Different Ethnic Populations.
• July, 2001 Alcon Laboratories Protocol CM-01-06: A Four Week Therapy Study of the Efficiency of Travatan 0.004% in Patients Whose Intraocular Pressure is not Adequately Controlled or Who are Intolerant to Other Intraocular Pressure Lowing Medications

PERSONAL

Born in Brooklyn, New York, 1961
Married to Carin and has two children, Zachary and Jared
Personal Interests/Activities: Enjoys Travel, Computers and Physical Fitness

YMCA Sarasota, Babe Weiler Branch, Member Board of Trustees